Meet our team member Susana!

Hi, I’m Susana Londono, a Research Manager at LDA Research, specialising in research across Latin America and Spain.

I joined LDA in June 2024, bringing with me a background in market research, having previously worked as a research analyst. My role involves managing projects from end to end, coordinating with clients and stakeholders, and leading recruitment activities to ensure we engage the right participants for each study. While my specialism is LATAM and Spain, I have the opportunity to work across a variety of global markets, which keeps every project interesting and different.

One of my favourite aspects of working at LDA is knowing that our work contributes to a much bigger purpose. Many of the projects we support help patients living with rare diseases continue to advocate for their conditions. It’s rewarding to know that the insights we gather can play a small part in the ongoing development of the medical and pharmaceutical industry, ultimately helping improve understanding, treatments and patient outcomes.

Outside of work, I enjoy hiking along the beautiful South Wales coastline with my partner and our dog Pep, spending time in the garden, and getting lost in a good book. I’ve also had the opportunity to live in 5 different countries (Colombia, US, New Zealand, England and Wales), which has given me a real appreciation for different cultures, perspectives and ways of life, something that I find invaluable in international research.

I’m proud to be part of the talented team at LDA Research and excited to continue contributing to meaningful projects that make a difference!

Share:

Facebook
X
LinkedIn
WhatsApp

More Blogs from LDA

The Ethics of Asking: Researching Sensitive Health Topics Well

Patient sensitivity is vital to medical market research. We believe an ethical approach to researching sensitive health topics is essential to good quality research. Ensuring a patient receives proper treatment is the baseline of our research and we employ case by case methods to ensure this. Ethical approaches toward patients guarantees better data quality, harm reduction, and patient satisfaction. When

Continue reading »

Rare Disease Networks Perspectives Series – Blog 3 out of 5: Policy, Protection, and Progress: The Regulatory Perspective on Rare Disease Networks

Regulation, by its nature, is cautious. Agencies tasked with protecting public health are not designed to move fast; they are designed to be rigorous. Yet rare diseases have, from the very beginning, placed regulators in an uncomfortable position. The same caution that protects patients from unsafe or ineffective treatments also, if applied without adaptation, denies those same patients access to

Continue reading »

From Orphan to Opportunity: The Evolution of Pharmaceutical Engagement in Rare Disease Networks

For most of the twentieth century, the pharmaceutical industry’s relationship with rare diseases could be summarised in a single phrase: studied indifference. The economics were simply prohibitive. Small patient populations meant limited revenue potential; limited revenue meant that even promising science rarely attracted the capital needed to progress from laboratory to clinic. The FDA estimated that in the decades before

Continue reading »

Contact us

Mandatory fields *